Melissa Sistrunk is a patent professional with over 27 years of experience prosecuting biotechnology and life sciences patent applications across a broad range of therapeutic and diagnostic technologies. Her practice has focused primarily on advanced biologics, cellular therapies, immuno-oncology and molecular diagnostics, with extensive exposure to cutting-edge platforms.
Melissa’s experience emphasizes the significant areas of immuno-oncology, cell and gene therapy, antibody therapeutics, molecular diagnostics, microbiome-based technologies and regenerative medicine, with a practice centered on the prosecution of complex biotechnology patent portfolios.
Her recent significant work includes:
- Obtaining patents related to cellular therapies and immunotherapies
- Obtaining patents related to chimeric antigen receptors
- Obtaining patents related to production of de-differentiated fibroblasts for various therapeutic purposes
- Support for transactional work related to MTA breaches and inventorship issues
- FTO work related to chimeric antigen receptor components
- FTO work related to immune cell therapies
Representative experience
- Therapeutics expertise includes chimeric antigen receptor (CAR) technologies, viral vector-based therapies, DNA and polypeptide therapeutics, antibody-based technologies (particularly scFv antibodies), T-cell receptor (TCR) therapies, cancer vaccines and CpG-related diagnostic innovations. She has also worked extensively with cell therapies involving NK cells, NKT cells, CAR-T cells, mesenchymal stem cells (MSCs), fibroblasts and chondrocytes, as well as organoid technologies and microbiome-based therapeutic approaches. Her experience spans both immunotherapy and regenerative medicine applications.
- Diagnostics experience centers on molecular and precision medicine technologies, including DNA-, genomic- and RNA-based diagnostics, gene expression monitoring, CpG-related diagnostic methods and biomarker-driven treatment decisions based on at least DNA methylation profiles. This work includes technologies analogous to companion diagnostics used to guide therapeutic selection and timing.
- Research tools and platform technologies experience includes innovations supporting cell engineering, CAR and TCR modification, organoid generation and manipulation and genomic expression analysis. These technologies provide foundational tools for therapeutic development, translational research and precision medicine applications
Education
PhD, Biochemistry and Cell Biology, Rice University, 1995
BS, magna cum laude and University Honors, Biochemistry, Texas A&M University, 1990
Melissa was a postdoctoral fellow at Baylor College of Medicine in the Human and Molecular Genetics Department and was funded through a National Institutes of Health Research Award. In 1999, she was registered before the U.S. Patent and Trademark Office.
Admissions
- US Patent and Trademark Agent
Speaking engagements
- "Plant Responses to the Environment: Regulation and Function of Arabidopsis TCH3," University of Houston Southwestern Developmental Biology Conference, Houston, Texas, May 1995
- "Sequence, Promoter Analysis, and Localization of Expression of TCH3, a Calmomodulin-Related Gene in Arabidopsis Thaliana," Lost Pines Molecular Biology Conference, Houston, Texas, October 1994
Publications
- "Telomerase, Ku, and Telometric Silencing in Saccharomyces Cerevisiae," Chromosoma, 1998
- "Arabidopsis Thaliana Responses to Mechanical Stimulation Do Not Require ETR1 or EIN2," Plant Physiology, 1998
- "Plant Responses to Environmental Stress: Regulations and Functions of the Arabidopsis TCH Genes," Planta, 1997
- "Arabidopsis TCH3 Encodes a Novel Ca2+ and Shows Environmentally Induced and Tissue-Specific Regulation," The Plant Cell, 1994
Membership and activities
- The Association of University Technology Managers
- Houston Intellectual Property Law Association